Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ampersand Capital Partners
Mandate

Vinge advises Ampersand Capital Partners

April 22, 2016

Vinge advises Ampersand Capital Partners, a Boston based private equity firm, in connection with the forming of the Gyros Protein Technologies group. The new group consists of Ampersand’s portfolio company Protein Technologies, Inc., a US based provider of peptide synthesis instrumentation and reagents, and the Swedish Gyros group operating within automated nanoliter-scale immunoassays, who’s majority owner is the Swedish Sixth National Pension Fund.
 
Vinge’s team consisted of, among others, the partner in charge Christina Kokko and Kristina Ekberg, Oscar Rydén and Maria Schultzberg.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025